A Paired, Double-Blind, Randomized Comparison of a Moisturizing Durable Barrier Cream to 10% Glycerine Cream in the Prophylactic Management of Postmastectomy Irradiation Skin Care: Trans Tasman Radiation Oncology Group (TROG) 04.01

被引:36
作者
Graham, Peter H. [1 ]
Plant, Natalie [1 ]
Graham, Jennifer L. [1 ]
Browne, Lois [1 ]
Borg, Martin [2 ]
Capp, Anne [3 ]
Delaney, Geoff P. [4 ]
Harvey, Jennifer [5 ]
Kenny, Lisbeth [6 ]
Francis, Michael [7 ]
Zissiadis, Yvonne [8 ]
机构
[1] St George Hosp, Canc Care Ctr, Kogarah, NSW 2217, Australia
[2] Royal Adelaide Hosp, Dept Radiat Oncol, Adelaide, SA, Australia
[3] Mater Hosp, Dept Radiat Oncol, Newcastle, NSW, Australia
[4] Liverpool Hosp, Canc Care Ctr, Liverpool, NSW, Australia
[5] Mater Hosp, South Brisbane, Qld, Australia
[6] Univ Queensland, Royal Brisbane Hosp, Herston, Qld, Australia
[7] Andrew Love Canc Ctr, Geelong, Vic, Australia
[8] Royal Perth Hosp, Dept Radiat Oncol, Perth, WA, Australia
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2013年 / 86卷 / 01期
关键词
PHASE-III TRIAL; SUCRALFATE CREAM; DERMATITIS; PREVENTION; THERAPY; TOXICITY; TROLAMINE; BIAFINE; CANCER; AGENT;
D O I
10.1016/j.ijrobp.2012.12.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A previous, unblinded study demonstrated that an alcohol-free barrier film containing an acrylate terpolymer (ATP) was effective in reducing skin reactions compared with a 10% glycerine cream (sorbolene). The different appearances of these products precluded a blinded comparison. To test the acrylate terpolymer principle in a double-blinded manner required the use of an alternative cream formulation, a moisturizing durable barrier cream (MDBC); the study was conducted by the Trans Tasman Radiation Oncology Group (TROG) as protocol 04.01. Methods and Materials: A total of 333 patients were randomized; 1 patient was ineligible and 14 patients withdrew or had less than 7 weeks' observations, leaving 318 for analysis. The chest wall was divided into medial and lateral compartments, and patients were randomized to have MDBC applied daily to the medial or lateral compartment and sorbolene to the other compartment. Weekly observations, photographs, and symptom scores (pain and pruritus) were collected to week 12 or resolution of skin reactions if earlier. Skin dose was confirmed by centrally calibrated thermoluminescent dosimeters. Results: Rates of medial and lateral compartment Common Toxicity Criteria (CTC), version 3, greater than or equal to grade 3 skin reactions were 23% and 41%, but rates by skin care product were identical at 32%. There was no significant difference between MDBC and sorbolene in the primary endpoint of peak skin reactions or secondary endpoints of area-under-the-curve skin reaction scores. Conclusions: The MDBC did not reduce the peak skin reaction compared to sorbolene. It is possible that this is related to the difference in the formulation of the cream compared with the film formulation. Skin dosimetry verification and double blinding are essential for radiation skin care comparative studies. (C) 2013 Elsevier Inc.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 20 条
[1]   Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis:: results from a double-blind, randomized study [J].
Boström, Å ;
Lindman, H ;
Swartling, C ;
Berne, B ;
Bergh, J .
RADIOTHERAPY AND ONCOLOGY, 2001, 59 (03) :257-265
[2]   Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck:: Results of radiation therapy oncology group trial 99-13 [J].
Elliott, EA ;
Wright, JR ;
Swann, RS ;
Nguyen-Tân, F ;
Takita, C ;
Bucci, MK ;
Garden, AS ;
Kim, H ;
Eugen, BH ;
Ryu, J ;
Greenberg, M ;
Saxton, JP ;
Ang, K ;
Berk, L .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2092-2097
[3]  
Fenig E, 2001, ONCOL REP, V8, P305
[4]   Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13 [J].
Fisher, J ;
Scott, C ;
Stevens, R ;
Marconi, B ;
Champion, L ;
Freedman, GM ;
Asrari, F ;
Pilepich, MV ;
Gagnon, JD ;
Wong, G .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (05) :1307-1310
[5]  
Freedberg IM., 1999, FITZPATRICKS DERMATO, V5
[6]  
Frocillo CA, IMPROVING RESIDENT C
[7]   Randomized, paired comparison of no-sting barrier film versus sorbolene cream (10% glycerine) skin care during postmastectomy irradiation [J].
Graham, P ;
Browne, L ;
Capp, A ;
Fox, C ;
Graham, J ;
Hollis, J ;
Nasser, E .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (01) :241-246
[8]   Digital photography as source documentation of skin toxicity: An analysis from the Trans Tasman Radiation Oncology Group (TROG) 04.01 Post-Mastectomy Radiation Skin Care Trial [J].
Graham, Peter H. ;
Plant, Natalie A. ;
Graham, Jennifer Louise ;
Browne, Lois H. ;
Borg, Martin ;
Capp, Anne ;
Delaney, Geoff P. ;
Harvey, Jennifer ;
Kenny, Lizbeth ;
Francis, Michael ;
Zissiadis, Yvonne .
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2012, 56 (04) :458-463
[9]  
Grove GL, 2012, COMP SKIN PROTECTANT
[10]   A DOUBLE-BLIND, RANDOMIZED, PROSPECTIVE TRIAL TO EVALUATE TOPICAL VITAMIN-C SOLUTION FOR THE PREVENTION OF RADIATION DERMATITIS [J].
HALPERIN, EC ;
GASPAR, L ;
GEORGE, S ;
DARR, D ;
PINNELL, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (03) :413-416